| Title |
|
Critical shortage in BCG immunotherapy: How did we get here and where will it take us? |
|
|
| Publication Date |
|
| Author(s) |
|
| Subject |
|
Bacillus Calmette-Guérin vaccine |
|
|
| Type of document |
|
| DOI |
|
10.1016/j.urolonc.2021.09.022 |
|
|
| Abstract |
|
Intravesical Bacillus Calmette-Guérin vaccine, one of the most successful bio-therapies to date, has been the gold standard treatment for non-muscle invasive bladder cancer for 44 years. International shortages have necessitated rationing this life-saving medication with deleterious effects on the primary treatment of high-grade non-muscle invasive bladder cancer. Understanding the history of intravesical Bacillus Calmette-Guérin gives us insight into the current shortages and future perspectives for novel immunotherapy opportunities against this deadly disease. |
|
|
| Link |
|
| Citation |
|
Urologic Oncology 2022; 40(1): 1-3 |
|
|
| Jornal Title |
|
